STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical
An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died. The drug, JNJ-6420, is designed to treat metastatic